Table 6.

Formulation of paclitaxel with PLGA, 0.05% SLS and poloxamer 407.

NO	Code	D:P (mg)	Size (nm)	PDI	Z.P (mv)	Amount Encapsulate (mg/mL)	(%) E.E	(%) Drug Loading
Poloxamer 407 (0.5 %)
01	PTX 100	1:10	180 ± 1.22	0.11 ± 0.01	–22.1 ± 1.5	0.64	64	6.4
02	PTX 101	2:10	184.6 ± 1.03	0.13 ± 0.01	−20.1 ± 1.1	0.90	45	9.0
03	PTX 102	3:10	190 ± 3.48	0.13 ± 0.03	−20.7 ± 1.8	1.83	61	18.3
04	PTX 103	4:10	202 ± 36.17	0.3 ± 0.01	−19.1 ± 1.5	2.12	53	21.2
Poloxamer 407 (1 %)
05	PTX 104	1:10	199 ± 21.80	0.4 ± 0.01	−26.85 ± 0.03	0.77	77	7.7
06	PTX 105	2:10	215 ± 18.72	0.6 ± 0.01	−24.1 ± 0.15	1.30	65	0.13
07	PTX 106	3:10	304 ± 12.99	0.6 ± 0.04	−26.8 ± 0.23	1.95	65	19.5
08	PTX 107	4:10	224 ± 26.98	0.8 ± 0.02	–23.08 ± 0.1	2.52	63	25.2
Poloxamer 407 (1.5 %)
09	PTX 108	1:10	202.3 ± 14.5	0.17 ± 0.03	−35.2 ± 0.12	0.89	89	8.9
10	PTX 109	2:10	215 ± 28.3	0.2 ± 0.03	−34.5 ± 0.03	1.42	71	14.2
11	PTX 110	3:10	300 ± 17.1	0.19 ± 0.02	−30.25 ± 0.25	1.95	65	19.5
12	PTX 111	4:10	331 ± 22.5	0.3 ± 0.01	−29.75 ± 0.11	2.28	57	22.8
Poloxamer 407 (2 %)
13	PTX 112	1:10	229 ± 13.24	0.2 ± 0.01	−40.4 ± 1.6	0.84	84	8.4
14	PTX 113	2:10	312 ± 12.41	0.3 ± 0.02	−39.08 ± 0.6	1.38	69	13.8
15	PTX 114	3:10	351 ± 10.49	0.3 ± 0.03	−34.21 ± 1.7	2.04	68	20.4
16	PTX 115	4:10	408 ± 11.27	0.7 ± 0.02	−28.11 ± 0.7	1.88	47	18.8

D: Paclitaxel, P: PLGA.